Am J Perinatol 1995; 12(3): 157-160
DOI: 10.1055/s-2007-994440
ORIGINAL ARTICLE

© 1995 by Thieme Medical Publishers, Inc.

The Monocyte Monolayer Assay: A Noninvasive Technique for Predicting the Severity of in Utero Hemolysis

Peter J. Larson, John M. Thorp Jr. , Richard C. Miller, Maureane Hoffman
  • Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology (J.M.T.), and Transfusion Medicine Service and Department of Pathology, University of North Carolina School of Medicine (P.J.L.), Chapel Hill, North Carolina; Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, National Naval Medical Center (R.C.N.), Bethesda, Maryland; and Durham Veterans Affairs Medical Center (M.H.), Durham, North Carolina
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. März 2008 (online)

ABSTRACT

To test the noninvasive monocyte monolayer assay in predicting hemolytic severity in utero, we studied 18 patients from two institutions with significant erythrocyte allo-antibodies. Serum samples were obtained from each patient. Each subject donated a serum sample during her pregnancy. Monocytes were harvested from a single healthy donor and grown in monolayer culture. Erythrocytes with the appropriate antigens were sensitized with maternal serum and incubated with the monocyte monolayers. Erythro-phagocytosis was scored as a percentage of the positive control. Perinatal outcomes were assessed post hoc and cases were classified as unaffected or mildly, moderately, or severely affected using standard definitions. Prenatal management was conducted without knowledge of the results. Six of the 18 patients had severe disease and one of the 18 had moderately severe disease. At a cutoff level of 20, the assay generated the following results: sensitivity was 7 of 7 (100%), specificity was 10 of 11 (90.9%), positive predictive value was 7 of 8 (87.5%), and negative predictive value was 10 of 10 (100%). The monocyte monolayer assay appears to be a useful, noninvasive modality for predicting the severity of hemolytic disease in utero.

    >